Last updated: 2026-09-08 01:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Cognition Therapeutics, Inc. (CGTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.03, with a market capitalisation of $97.95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.55 to $2.60. This page covers its latest market performance, valuation, price trends and company information.
$97.95M | |
$1.05 | |
$13.80 | |
$0.22 | |
$1.05 | |
371.67K | |
1.18M | |
-- | |
$2.60 | |
$0.55 | |
-- | |
-- |
Cognition Therapeutics, Inc. (CGTX) last closed at $1.05 as of 2026-09-04 23:59:00, unchanged from the previous close of $1.05.
During the latest regular trading session, CGTX traded between $0.22 and $13.80, with a volume of 371.67K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Cognition Therapeutics, Inc. (CGTX) moved from $1.06 to $1.03, representing a decline of 2.92% ($0.03).
The stock traded between $0.98 and $1.08 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 324.23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 23.4%
CGTX is currently trading at $1.03, placing it 23.4% of the way from its 52-week low of $0.55 to its 52-week high of $2.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cognition Therapeutics, Inc. (CGTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.